Does dexrazoxane provide cardioprotection without compromising safety or efficacy in children and adolescents treated with doxorubicin-containing chemotherapy for newly diagnosed T-cell acute lymphoblastic leukemia or advanced-stage lymphoblastic non-Hodgkin lymphoma?
Dexrazoxane safely provides cardioprotection without compromising antitumor efficacy in pediatric patients receiving anthracycline-based chemotherapy.
Dexrazoxane was cardioprotective and did not compromise antitumor efficacy, did not increase the frequencies of toxicities, and was not associated with a significant increase in second malignancies with this doxorubicin-containing chemotherapy regimen. We recommend dexrazoxane as a cardioprotectant for children and adolescents who have malignancies treated with anthracyclines.
Asselin et al. (Wed,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: